Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) shares shot up 11% during trading on Tuesday . The stock traded as high as $0.11 and last traded at $0.10. 155,128 shares changed hands during mid-day trading, an increase of 78% from the average session volume of 86,940 shares. The stock had previously closed at $0.09.
Bioxytran Price Performance
The stock has a market cap of $18.57 million, a PE ratio of -3.49 and a beta of -0.90. The business has a 50 day moving average price of $0.10 and a two-hundred day moving average price of $0.11.
About Bioxytran
Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.
Further Reading
- Five stocks we like better than Bioxytran
- What Are Growth Stocks and Investing in Them
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- 3 REITs to Buy and Hold for the Long Term
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
